Results 111 to 120 of about 117,976 (202)

Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats. [PDF]

BMC Gastroenterol, 2023
Skarbaliene J, Mathiesen JM, Larsen BD, Thorkildsen C, Petersen YM.   +4 more
europepmc   +1 more source

Glucagon-Like Peptide-2 Stimulates S-Phase Entry of Intestinal Lgr5+ Stem Cells. [PDF]

Cell Mol Gastroenterol Hepatol, 2022
Chen ME, Naeini SM, Srikrishnaraj A, Drucker DJ, Fesler Z, Brubaker PL.   +5 more
europepmc   +1 more source

Short- versus long-term, gender and species differences in the intestinotrophic effects of long-acting glucagon-like peptide 2 analog. [PDF]

Physiol Res, 2022
Glerup P, Sonne K, Berner-Hansen M, Skarbaliene J.   +3 more
europepmc   +1 more source

Glucagon-like peptide 2 and inflammatory bowel disease

, 2000
Bibliography: p.
openaire   +2 more sources

Integrative analysis revealed the role of glucagon-like peptide-2 in improving experimental colitis in mice by inhibiting inflammatory pathways, regulating glucose metabolism, and modulating gut microbiota. [PDF]

Front Microbiol, 2023
Li D, Gao Y, Cui L, Li Y, Ling H, Tan X, Xu H.   +6 more
europepmc   +1 more source

Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy Men. [PDF]

J Endocr Soc
Sørum NE, Magnussen T, Hansen NL, Nielsen CK, Holst JJ, Hartmann B, Henriksen K, Størling J, Faber J, Christensen MB, Lund AB, Knop FK.   +11 more
europepmc   +1 more source

Contribution of Vasoactive Intestinal Peptide to the Depressant Effects of Glucagon-like Peptide-2 on Neurally Induced Contractile Responses in Mouse Ileal Preparations. [PDF]

Int J Mol Sci
Baccari MC, Conti D, Vannucchi MG, Idrizaj E.   +3 more
europepmc   +1 more source

Glucagon-Like Peptide-2 (GLP-2) Analogues in Patients With Short Bowel Syndrome Dependent on Parenteral Support: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

JGH Open
Hyder A, Alria A, Rafiq A, Akram MF, Hassan T, Ali EF, Vhora F, Khan S, Zahra SG, Niazi MA, Jafar U, Cheema HA, Alsubari AMA, Altaf F, Bhat A, Rashad E, Jalal PK.   +16 more
europepmc   +1 more source

Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial. [PDF]

JPEN J Parenter Enteral Nutr, 2023
Naimi RM, Hvistendahl MK, Poulsen SS, Kissow H, Pedersen J, Nerup NA, Ambrus R, Achiam MP, Svendsen LB, Jeppesen PB.   +9 more
europepmc   +1 more source

Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome. [PDF]

JCI Insight
Kudo Y, Miyamoto K, Suzuki S, Chida A, Tojo A, Hasegawa M, Shigehara A, Koya I, Ando Y, Sato M, Kondo A, Kumagai T, Deguchi H, Sugiyama Y, Ito Y, Shirosaki K, Yamagishi S, Maeda Y, Kanamori H, Kano M, Kato M, Tsujikawa H, Yoshimatsu Y, Takabayashi K, Okabayashi K, Kanai T, Hosoe N, Kato M, Moody J, Hon CC, Kuroda T, Yamada Y, Fujino A, Sujino T.   +33 more
europepmc   +1 more source